Frontlight ResearchEarly access
Active, not recruitingPhase 2
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70 Years of Age)
Key facts
- Who runs it
- ModernaTX, Inc.
- Where
- Canada8 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 2
- People taking part
- 366 people enrolled
- Started
- 29 Apr 2026
- Expected to end
- 9 Nov 2028
- Type of study
- Interventional, 2 groups
- Treatments tested
- mRNA-1982
- Placebo
- Record updated
- 3 August 2026
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- In good general health in the opinion of the investigator as determined by medical evaluation including medical history and physical examination at screening
- Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
Who cannot take part
- Received treatment for Lyme disease within the prior 3 months
- Previously vaccinated against Lyme disease or participated in the past in any vaccine study for Lyme disease
- Had a tick bite within 4 weeks prior to Day 1; Note: Additional inclusion/exclusion criteria may apply, per protocol
- History of anaphylaxis or severe hypersensitivity reaction requiring medical intervention after receipt of any mRNA vaccine or therapeutic or any components of an mRNA vaccine or therapeutic
- Have chronic illness related to Lyme disease or an active symptomatic Lyme disease infection as suspected or diagnosed by a physician
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This clinical study will evaluate the safety, reactogenicity, and immunogenicity of monovalent mRNA-1982, a messenger ribonucleic acid (mRNA) vaccine to prevent Lyme disease in healthy adults aged 18 to 70 years old.
The 2 groups in the trial
- Dose-finding PhaseTreatment being tested
Participants will receive mRNA-1982 or placebo as an intramuscular injection.
Treatment: mRNA-1982 and Placebo
- Booster PhaseTreatment being tested
Participants will receive mRNA-1982 (as a booster) or placebo as an intramuscular injection.
Treatment: mRNA-1982 and Placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 2, Randomized, Observer-blind, Dose-finding, Placebo-controlled Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982, an mRNA Vaccine to Prevent Lyme Disease in Healthy Adult Participants (18 to 70 Years of Age)
- Record updated
- 3 August 2026